Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Prekallikrein-directed antisense oligonucleotides
3 evidence topics · 3 sources
Donidalorsen: prophylaxis and dosing interval
Donidalorsen: indication, mechanism, and dosing
Donidalorsen: guideline summary of efficacy by dosing interval
“Donidalorsen is an antisense oligonucleotide that blocks the production of prekallikrein in the liver, which is primarily synthesized in the liver.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Efficacy of every 4- and 8-weeks injections was 81% and 55%, respectively, compared to placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Because of a delay in onset of the donidalorsen, when data were compared to placebo starting at week 5, the 4- and 8-weeks dose reduced attacks by 87% and 60%, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote